Moberg Pharma (Sweden) Insiders
| MOB Stock | SEK 18.26 0.93 4.85% |
Moberg Pharma employs about 7 people. The company is managed by 6 executives with a total tenure of roughly 17 years, averaging almost 2.0 years of service per executive, having 1.17 employees per reported executive. Breaking down Moberg Pharma's management performance can provide insight into the firm performance.
| Mark Beveridge Insider VP Fin |
| Anders Broijersen Insider Chief Officer |
Moberg |
Moberg Pharma Management Team Effectiveness
The company has return on total asset (ROA) of (0.0249) % which means that it has lost $0.0249 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0325) %, meaning that it generated substantial loss on money invested by shareholders. Moberg Pharma's management efficiency ratios could be used to measure how well Moberg Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Moberg Pharma Workforce Comparison
Moberg Pharma AB is rated below average in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is now estimated at about 9,213. Moberg Pharma adds roughly 7.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
Moberg Pharma AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Moberg Pharma AB Price Series Summation is a cross summation of Moberg Pharma price series and its benchmark/peer.
Moberg Pharma Notable Stakeholders
A Moberg Pharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Moberg Pharma often face trade-offs trying to please all of them. Moberg Pharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Moberg Pharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Mark Beveridge | VP Fin | Profile | |
| Anders Broijersen | Chief Officer | Profile | |
| MSc BA | Chief Officer | Profile | |
| Kerstin Strinnholm | Ex Chairman | Profile | |
| Marie Moberg | CoFounder | Profile | |
| Gunilla Wengstrm | Director Marketing | Profile |
About Moberg Pharma Management Performance
The success or failure of an entity such as Moberg Pharma AB often depends on how effective the management is. Moberg Pharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Moberg management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Moberg management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Moberg Pharma AB , a pharmaceutical company, develops and commercializes medical products for pain and skin conditions in Europe, the United States, and internationally. Moberg Pharma AB was incorporated in 2006 and is headquartered in Bromma, Sweden. Moberg Pharma operates under Drug ManufacturersSpecialty Generic classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people.
Please note, the imprecision that can be found in Moberg Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Moberg Pharma AB. Check Moberg Pharma's Beneish M Score to see the likelihood of Moberg Pharma's management manipulating its earnings.
Moberg Pharma Workforce Analysis
Traditionally, organizations such as Moberg Pharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Moberg Pharma within its industry.Moberg Pharma Manpower Efficiency
Return on Moberg Pharma Manpower
| Revenue Per Employee | 30M | |
| Revenue Per Executive | 34.9M | |
| Net Income Per Employee | 1.1M | |
| Net Income Per Executive | 1.2M | |
| Working Capital Per Employee | 51.4M | |
| Working Capital Per Executive | 60M |
Additional Tools for Moberg Stock Analysis
When running Moberg Pharma's price analysis, check to measure Moberg Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moberg Pharma is operating at the current time. Most of Moberg Pharma's value examination focuses on studying past and present price action to predict the probability of Moberg Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moberg Pharma's price. Additionally, you may evaluate how the addition of Moberg Pharma to your portfolios can decrease your overall portfolio volatility.